| Tammy K Mayer, RN, MPH | |
|
1585 3rd St, Fort Polk, LA 71459-5102 | |
| (337) 531-4740 | |
| (337) 531-6764 |
| Full Name | Tammy K Mayer |
|---|---|
| Gender | Female |
| Speciality | Registered Nurse - Community Health |
| Location | 1585 3rd St, Fort Polk, Louisiana |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1649231119 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 163WC1500X | Registered Nurse - Community Health | 135276 (Missouri) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Tammy K Mayer, RN, MPH 1585 3rd St, Fort Polk, LA 71459-5102 Ph: (337) 531-4740 | Tammy K Mayer, RN, MPH 1585 3rd St, Fort Polk, LA 71459-5102 Ph: (337) 531-4740 |
News Archive
Use of a patient's bone marrow cells for treating chronic ischemic heart failure did not result in improvement on most measures of heart function, according to a study appearing in JAMA. The study is being published early online to coincide with its presentation at the American College of Cardiology's annual scientific sessions.
Despite strong community opposition and media attention, the Vancouver Coastal Health Authority continues to dismantle the outpatient Domestic Violence Program at Vancouver General Hospital. The 18-year-old program is slated to close at the end of this week.
An international research consortium co-led by Andrea L. Gropman, M.D., at Children's National Hospital has received $5 million in federal funding as part of an overall effort to better understand rare diseases and accelerate potential treatments to patients.
A new model that can be used to guide health care financing and resource allocation decisions in the U.S. has been developed by an international group of researchers led by a team from the University of Illinois at Chicago.
Promedior, Inc., a clinical stage biotechnology company developing novel therapeutics for the treatment of fibrosis, today announced that principal investigator, Srdan Verstovsek, MD, PhD, will present interim data from the Company's ongoing Phase 2 clinical trial of its lead product candidate, PRM-151, for the treatment of myelofibrosis, in a poster presentation on June 2, 2014 at the American Society for Clinical Oncology 2014 Annual Meeting.
› Verified 6 days ago
Mrs. Katrina Lynn Shores, RN/NCM Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 1585 3rd St, Fort Polk, LA 71459 Phone: 337-531-3318 | |
Kristy Renee Mccomic, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 1585 3rd Street Building 285, Attention: Credentials, Room 7064, Fort Polk, LA 71459 Phone: 337-531-3561 | |
Paul Swindle Jr., RN, CCM Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 1585 3rd St Bldg 285, Fort Polk, LA 71459 Phone: 337-531-0298 | |
Mrs. Carolyn Evodney Turner-walter, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 1585 3rd St, Fort Polk, LA 71459 Phone: 337-531-3774 Fax: 337-531-0408 | |
Rodolfo Quintana, Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 1585 3rd St, Fort Polk, LA 71459 Phone: 337-531-7961 | |
Julianne Kossman, RN/CCM Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 1585 3rd St Bldg 285, Fort Polk, LA 71459 Phone: 337-653-3258 |